Drug intelligence / Profile preview

CE211BR19

Development stage: Unknown
Lead developer: Corestemchemon
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrathecal

Overview

CE211BR19 (also known as HYNR-CS-Allo) is an allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy developed by Corestemchemon for the treatment of neurodegenerative disorders, specifically cerebellar ataxia (CA). The therapy consists of HLA-haplo matched allogeneic MSCs administered intrathecally as a suspension. It is designed to exert neuroprotective and immunomodulatory effects, aiming to address the underlying pathology of cerebellar degeneration where treatment options are currently limited. The program is currently in Phase 1 clinical development.

Other names: HYNR-CS-Allo

Beyond the preview

Go deeper on CE211BR19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CE211BR19.

Explore the full profile